Picture of Camurus AB logo

CAMX — Camurus AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Brief: Camurus Reiterates FY 2026 Outlook

BRIEF-Camurus Reiterates FY 2026 Outlook

- Camurus AB CAMX.ST:

  • Q3 EBIT SEK 322 MILLION

  • Q3 REVENUE SEK 724 MILLION VERSUS. IBES ESTIMATE SEK 691.2 MILLION

  • Q3 2026 PRODUCT SALES INCREASED 28% TO MSEK 582

  • 2026 OUTLOOK REITERATED

  • DURING QUARTER, FDA ACCEPTED RESUBMISSION OF NDA FOR CAM2029 FOR REVIEW IN ACROMEGALY AND OCZYESA WAS APPROVED IN AUSTRALIA

  • HEALTH CANADA APPROVES OCZYESA XR FOR ACROMEGALY

Source text: ID:nWkr2kJSLq

Further company coverage: CAMX.ST


(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Camurus AB

See all news